Response of advanced HCC to pembrolizumab and lenvatinib combination therapy despite monotherapy failure.
Sign Up to like & getrecommendations! Published in 2020 at "Zeitschrift fur Gastroenterologie"
DOI: 10.1055/a-1190-5681
Abstract: In recent years, immune checkpoint inhibitors (ICIs) were successfully introduced to cancer therapy, and these drugs have already become essential for the treatment of various noncurable tumors. However, monotherapy in advanced hepatocellular carcinoma (aHCC) failed… read more here.
Keywords: combination; response advanced; therapy despite; therapy ... See more keywords